Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Myofilament-based physiological regulatory compensation preserves diastolic function in failing hearts with severe Ca2+ handling deficits
Frazer I. Heinis, Brian R. Thompson, Rishi Gulati, Matthew Wheelwright, Joseph M. Metzger
Frazer I. Heinis, Brian R. Thompson, Rishi Gulati, Matthew Wheelwright, Joseph M. Metzger
View: Text | PDF
Research Article Cardiology

Myofilament-based physiological regulatory compensation preserves diastolic function in failing hearts with severe Ca2+ handling deficits

  • Text
  • PDF
Abstract

Severe dysfunction in cardiac muscle intracellular Ca2+ handling is a common pathway underlying heart failure. Here we used an inducible genetic model of severe Ca2+ cycling dysfunction by the targeted temporal gene ablation of the cardiac Ca2+ ATPase, SERCA2, in otherwise normal adult mice. In this model, in vivo heart performance was minimally affected initially, even though Serca2a protein was markedly reduced. The mechanism underlying the sustained in vivo heart performance in the weeks prior to complete heart pump failure and death is not clear and is important to understand. Studies were primarily focused on understanding how in vivo diastolic function could be relatively normal under conditions of marked Serca2a deficiency. Interestingly, data show increased cardiac troponin I (cTnI) serine 23/24 phosphorylation content in hearts upon Serca2a ablation in vivo. We report that hearts isolated from the Serca2-deficient mice retained near normal heart pump functional responses to β-adrenergic stimulation. Unexpectedly, using genetic complementation models, in concert with inducible Serca2 ablation, data show that Serca2a-deficient hearts that also lacked the central β-adrenergic signaling–dependent Serca2a negative regulator, phospholamban (PLN), had severe diastolic dysfunction that could still be corrected by β-adrenergic stimulation. Notably, integrating a serines 23/24–to–alanine PKA-refractory sarcomere incorporated cTnI molecular switch complex in mice deficient in Serca2 showed blunting of β-adrenergic stimulation–mediated enhanced diastolic heart performance. Taken together, these data provide evidence of a compensatory regulatory role of the myofilaments as a critical physiological bridging mechanism to aid in preserving heart diastolic performance in failing hearts with severe Ca2+ handling deficits.

Authors

Frazer I. Heinis, Brian R. Thompson, Rishi Gulati, Matthew Wheelwright, Joseph M. Metzger

×

Figure 4

Effects of PLN gene KO on LV performance in Serca2 gene–ablated hearts.

Options: View larger image (or click on image) Download as PowerPoint
Effects of PLN gene KO on LV performance in Serca2 gene–ablated hearts.
...
(A) SERCA2-KO × PLN-KO breeding diagram. Serca2fl/fl mice were crossed with PLN–/– (PLN-KO) mice lacking the key SERCA2 inhibitor, phospholamban (PLN). F1 heterozygous siblings were crossed, and the Serca2-FL and PLN-KO alleles were bred to homozygosity. These mice either expressed (TG) or did not express (NTG) the αMHC-MerCreMer transgene allowing for Serca2 gene disruption upon tamoxifen injection. For experiments using these mice, all animals lacked PLN and were either Serca2fl/fl (PLN-KO;Serca2-FL) or Serca2-KO (PLN-KO;Serca2-KO). (B–D) Serca2fl/fl;PLN–/– mice were injected with tamoxifen (40 mg/kg i.p. in peanut oil) to induce Serca2 KO in mice expressing MerCreMer recombinase. Hearts were excised from SERCA2-FL or SERCA2-KO mice and evaluated by Langendorff perfusion. Hearts were equilibrated for 15 minutes in normal Krebs (vehicle), paced from 7 to 12 Hz in 1 Hz increments, and reequilibrated for 10 minutes at 7 Hz before switching perfusion to a reservoir containing 50 nM isoproterenol in Krebs. The 7–12 Hz pacing challenge was repeated, and hearts were returned to normal Krebs at 7 Hz for 10 minutes. (B) Representative original LV pressure recordings in Serca2 FL and KO hearts with complete PLN deficiency and in the presence or absence of acute β-adrenergic stimulation. (C) LVEDP during pacing challenge. At baseline, end-diastolic pressures in FL hearts do not rise above preload levels, whereas KO hearts are unable to relax fully at high pacing frequencies. After perfusion with 50 nM isoproterenol, KO hearts relax fully at all pacing frequencies, indicating an intact lusitropic effect of isoproterenol in a PLN–/– heart. ***P < 0.05 for KO (no Iso) versus all other groups at that pacing frequency. (D) LVEDP at maximum pacing frequency in SERCA2-KO; PLN–/– hearts. Serca2-KO; PLN–/– hearts are unable to relax fully at high pacing frequencies. This impaired relaxation performance is corrected upon isoproterenol perfusion. Groups were compared using 1-way ANOVA with Bonferroni post hoc tests. **P < 0.01. n = 9 per group. (E) T50 Relax at 7Hz ***P < 0.001, **P = 00.012, *P = 0.0171 using 1-way ANOVA with Tukey post hoc test. (F) Western blots for SERCA2, p-cTnI, and total cTnI in PLN-KO hearts. C, a control SERCA replete heart sample; M, Marker. n = 5 per group.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts